PMID- 34541760
OWN - NLM
STAT- MEDLINE
DCOM- 20220331
LR  - 20220401
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
VI  - 38
IP  - 2
DP  - 2022 Feb
TI  - Monocyte chemoattractant protein-1 predicts the development of diabetic 
      nephropathy.
PG  - e3497
LID - 10.1002/dmrr.3497 [doi]
AB  - AIM: Diabetic nephropathy (DN) is a devastating complication of diabetes mellitus 
      (DM). Therefore, screening strategies in order to prevent its development and/or 
      retard its progression are of paramount importance. We investigated if monocyte 
      chemoattractant protein-1 (MCP-1) was associated with new onset 
      microalbuminuria-the earliest sign of the albuminuric phenotype of DN- in 
      patients with type 2 DM and normoalbuminuria. METHODS: We measured MCP-1 in serum 
      and urine samples from patients of the Randomized Olmesartan And Diabetes 
      Microalbuminuria Prevention (ROADMAP) study and its Observational Follow-up (OFU) 
      cohort. A case control design was used with inclusion of 172 patients who 
      developed microalbuminuria (MA) and of 188 well matched controls who remained 
      normoalbuminuric. RESULTS: The median duration of follow-up for the ROADMAP 
      cohorts was 6.5 years, whereas the mean time until occurrence of MA was 53.2 
      months. In the multivariate analysis, serum and urine MCP-1 remained significant 
      predictors of new onset MA. The risk for MA increased continuously with 
      increasing serum and urine MCP-1 levels but reached statistical significance only 
      in the highest quartiles. The risk associations were stronger with serum MCP-1. 
      CONCLUSIONS: MCP-1 is a marker and possibly a mediator of early diabetic 
      nephropathy. Further prospective studies are necessary to test whether diabetic 
      patients with elevated MCP-1 levels would benefit from specific therapeutic 
      interventions.
CI  - (c) 2021 The Authors. Diabetes/Metabolism Research and Reviews published by John 
      Wiley & Sons Ltd.
FAU - Scurt, Florian G
AU  - Scurt FG
AUID- ORCID: 0000-0001-6197-4720
AD  - Clinic of Nephrology, Hypertension, Diabetes and Endocrinology, Otto-von-Guericke 
      University Magdeburg, Magdeburg, Germany.
FAU - Menne, Jan
AU  - Menne J
AD  - Department of Nephrology, KRH Hospital Siloah, Klinikum Region Hannover GmbH, 
      Hanover, Germany.
FAU - Brandt, Sabine
AU  - Brandt S
AD  - Clinic of Nephrology, Hypertension, Diabetes and Endocrinology, Otto-von-Guericke 
      University Magdeburg, Magdeburg, Germany.
FAU - Bernhardt, Anja
AU  - Bernhardt A
AD  - Clinic of Nephrology, Hypertension, Diabetes and Endocrinology, Otto-von-Guericke 
      University Magdeburg, Magdeburg, Germany.
FAU - Mertens, Peter R
AU  - Mertens PR
AD  - Clinic of Nephrology, Hypertension, Diabetes and Endocrinology, Otto-von-Guericke 
      University Magdeburg, Magdeburg, Germany.
FAU - Haller, Hermann
AU  - Haller H
AD  - Nephrology Section, Hanover Medical School, Hanover, Germany.
FAU - Chatzikyrkou, Christos
AU  - Chatzikyrkou C
AD  - Nephrology Section, Hanover Medical School, Hanover, Germany.
AD  - PHV-Dialysis Center, Halberstadt, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211012
PL  - England
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
RN  - 0 (Chemokine CCL2)
SB  - IM
MH  - Albuminuria/diagnosis
MH  - Chemokine CCL2/therapeutic use/urine
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - *Diabetic Nephropathies/diagnosis/etiology
MH  - Humans
MH  - Prospective Studies
OTO - NOTNLM
OT  - MCP-1
OT  - ROADMAP
OT  - chronic kidney disease
OT  - diabetes mellitus
OT  - diabetic nephropathy
OT  - microalbuminuria
EDAT- 2021/09/21 06:00
MHDA- 2022/04/01 06:00
CRDT- 2021/09/20 06:37
PHST- 2021/08/18 00:00 [revised]
PHST- 2021/06/10 00:00 [received]
PHST- 2021/08/22 00:00 [accepted]
PHST- 2021/09/21 06:00 [pubmed]
PHST- 2022/04/01 06:00 [medline]
PHST- 2021/09/20 06:37 [entrez]
AID - 10.1002/dmrr.3497 [doi]
PST - ppublish
SO  - Diabetes Metab Res Rev. 2022 Feb;38(2):e3497. doi: 10.1002/dmrr.3497. Epub 2021 
      Oct 12.